Clinical Trials Browser

INDUSTRY × Recurrence × pomalidomide × Clear all

NCT06615479 2026-03-17

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Phase 3 Recruiting

440 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT05519085 2026-03-11

SUCCESSOR-1

Phase 3 Recruiting

810 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT07138209 2026-02-27

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Recruiting

228 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT05455320 2026-01-16

MonumenTAL-3

Phase 3 Active not recruiting

864 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT07312188 2025-12-31

A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Phase 2 Recruiting

90 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT02343042 2025-12-22

STOMP

Phase 1/2 Recruiting

300 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT04191616 2025-09-04

SELECT

Phase 2 Completed

54 enrolled 17 charts

Plasma cell

Multiple Myeloma, Recurrence

NCT06163040 2025-07-31

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Completed

7 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT03539744 2025-06-19

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Phase 3 Active not recruiting

265 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

NCT03288974 2025-04-15

Pomalyst PMS

Completed

397 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT02616640 2024-09-19

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Phase 1 Completed

114 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT02294357 2023-11-01

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Phase 2 Terminated

45 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT02206425 2023-10-31

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Phase 1/2 Completed

45 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT04895410 2023-03-06

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

Phase 1 Terminated

8 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

NCT03439280 2023-02-24

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

Phase 1/2 Completed

50 enrolled 26 charts

Plasma cell

Multiple Myeloma, Recurrence

NCT03651128 2022-12-15

KarMMa-3

Phase 3 Active not recruiting

381 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT05236621 2022-02-11

A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Phase 3 Unknown

85 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT01712789 2022-01-10

STRATUS

Phase 3 Completed

682 enrolled 23 charts

Plasma cell

Multiple Myeloma, Recurrence

NCT01497093 2020-04-07

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1 Completed

34 enrolled

Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT02189343 2019-11-21

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Phase 1 Completed

16 enrolled

Plasma cell

Disease, Multiple Myeloma, Recurrence, Disease Progression

NCT01324947 2019-11-19

Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma

Phase 3 Completed

74 enrolled 17 charts

Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01632826 2019-11-12

PEXIUS

Approved for marketing

Plasma cell

Multiple Myeloma, Recurrence

NCT02103335 2017-11-22

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

Phase 1 Completed

38 enrolled

Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT02011113 2016-11-01

Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma

Phase 2 Completed

36 enrolled 18 charts

Plasma cell

Multiple Myeloma, Recurrence